{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-082237","form_type":"8-K","ticker":"ORMP","cik":"0001176309","company_name":"ORAMED PHARMACEUTICALS INC.","filed_at":"2024-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.347580+00:00","generated_at":"2026-05-31T01:26:08.098016+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Oramed signs $11.5M CRO agreement for Phase 3 trial of ORMD-0801 in type 2 diabetes","bullets":["Oramed Ltd. subsidiary retained InClin as CRO for planned Phase 3 trial of oral insulin candidate ORMD-0801.","Trial to assess safety/efficacy in approximately 300 type 2 diabetes patients under US IND.","Total consideration up to ~$11.5 million, paid monthly based on hours performed over engagement.","Sponsor can terminate with or without cause on 30 days' notice; standard cure period for breach."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-082237","json":"https://secwatch.observer/filing/0001213900-24-082237.json","markdown":"https://secwatch.observer/filing/0001213900-24-082237.md","text":"https://secwatch.observer/filing/0001213900-24-082237.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1176309/000121390024082237/0001213900-24-082237-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1176309/000121390024082237/ea0215648-8k_oramed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T01:26:08.098016+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}